# US 2015/0105443 A1 · Single-stranded nucleic acid molecule for regulating expression of gene having delivering function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105443 A1
- Document ID: US20150105443A1
- Status: Published application
- Kind: A1
- Application number: 14/403,259
- Filed: 2013-05-25
- Published: 2015-04-16
- Earliest claimed: 2012-05-26
- Assignees: Bonac Corporation
- Applicants: Bonac Corporation
- Inventors: Tadaaki Ohgi; Eriko Aoki; Chisato Emura; Tomohiro Hamasaki
- Web page: https://patentgrep.com/patent/US20150105443A1

## CPC

- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/544: {Phospholipids}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2310/533: having a mismatch or nick in at least one of the strands
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides a single-stranded nucleic acid capable of inhibiting expression of a target gene having a delivery function. The nucleic acid contains, from the 5′-side to the 3′-side, a 5′-side region (Xc), a linker region (Lx), an inner region (Z), a linker region (Ly) and a 3′-side region (Yc) in this order, wherein the inner region (Z) is constituted by linkage of the inner 5′-side region (X) and the inner 3′-side region (Y), the 5′-side region (Xc) is complementary to the inner 5′-side region (X), the 3′-side region (Yc) is complementary to the inner 3′-side region (Y), at least one of the inner region (Z), the 5′-side region (Xc) and the 3′-side region (Yc) comprises an expression inhibitory sequence that inhibits expression of a target gene, and at least one of the 5′-terminus, the 3′-terminus, the linker region (Lx) and the linker region (Ly) is bound to a bio-related substance.

## Claims

### Claim 1

An isolated single-stranded nucleic acid molecule for inhibiting expression of a target gene having a delivery function, which comprises, from the 5′-side to the 3′-side, a 5′-side region (Xc), a linker region (Lx), an inner region (Z), a linker region (Ly) and a 3′-side region (Yc) in this order, wherein
the aforementioned inner region (Z) is constituted by linkage of the inner 5′-side region (X) and the inner 3′-side region (Y),
the aforementioned 5′-side region (Xc) is complementary to the aforementioned inner 5′-side region (X),
the aforementioned 3′-side region (Yc) is complementary to the aforementioned inner 3′-side region (Y),
at least one of the aforementioned inner region (Z), the aforementioned 5′-side region (Xc) and the aforementioned 3′-side region (Yc) comprises an expression inhibitory sequence that inhibits expression of a target gene, and
at least one selected from the group consisting of the 5′-terminus, the 3′-terminus, the aforementioned linker region (Lx) and the aforementioned linker region (Ly) is bound to a bio-related substance.

### Claim 2 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, wherein the bio-related substance is a lipid.

### Claim 3 (depends on 2)

The single-stranded nucleic acid molecule according to claim 2, wherein the bio-related substance is simple lipid, complex lipid, derived lipid, single-chain lipid, double-chain lipid, glycolipid, liposoluble vitamin or steroid.

### Claim 4 (depends on 2)

The single-stranded nucleic acid molecule according to claim 2, wherein the lipid is at least one selected from the group consisting of palmitic acid, myristic acid, stearic acid and oleic acid.

### Claim 5 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, wherein the bio-related substance is at least one selected from the group consisting of antibody protein, peptide thereof and membrane-permeable peptide.

### Claim 6 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, which satisfies the following conditions of the formulas (1) and (2):
Z=X+Y (1)
Z≧Xc+Yc (2)
wherein Z is a base number of the inner region (Z), X is a base number of the inner 5′-side region (X), Y is a base number of the inner 3′-side region (Y), Xc is a base number of the 5′-side region (Xc) and Yc is a base number of the 3′-side region (Yc).

### Claim 7 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, which comprises at least one modified residue.

### Claim 8 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, which comprises a stable isotope.

### Claim 9 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, wherein the linker region (Lx) and/or the linker region (Ly) is/are composed of at least one of a nucleotide residue and a non-nucleotide residue.

### Claim 10 (depends on 9)

The single-stranded nucleic acid molecule according to claim 9, wherein the nucleotide residue is a non-modified nucleotide residue and/or a modified nucleotide residue.

### Claim 11 (depends on 9)

The single-stranded nucleic acid molecule according to claim 9, wherein the linker region (Lx) and/or the linker region (Ly) is/are composed of any of the residues of the following (1)-(7):
(1) a non-modified nucleotide residue
(2) a modified nucleotide residue
(3) a non-modified nucleotide residue and a modified nucleotide residue
(4) a non-nucleotide residue
(5) a non-nucleotide residue and a non-modified nucleotide residue
(6) a non-nucleotide residue and a modified nucleotide residue
(7) a non-nucleotide residue, a non-modified nucleotide residue and a modified nucleotide residue.

### Claim 12 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, wherein the gene expression inhibition is an expression inhibition by RNA interference.

### Claim 13 (depends on 1)

The single-stranded nucleic acid molecule according to claim 1, wherein the base sequence of the single-stranded nucleic acid molecule is the base sequence of SEQ ID NO: 5, 6, 11, 12, 13, 14, 15 or 16.

### Claim 14 (depends on 1)

A composition for inhibiting an expression of a target gene, comprising a single-stranded nucleic acid molecule according to claim 1.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a single-stranded nucleic acid molecule according to claim 1.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method of inhibiting an expression of a target gene, comprising using a single-stranded nucleic acid molecule according to claim 1.

### Claim 18 (depends on 17)

The method according to claim 17, comprising a step of administering the single-stranded nucleic acid molecule to a cell, tissue or organ.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the single-stranded nucleic acid molecule is administered in vivo or in vitro.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the gene expression inhibition is an expression inhibition by RNA interference.

### Claim 21 (depends on 1)

A method of inducing RNA interference to inhibit expression of a target gene, comprising using a single-stranded nucleic acid molecule according to claim 1.

### Claim 22 (depends on 1)

A method of treating disease, comprising a step of administering a single-stranded nucleic acid molecule according to claim 1 to a patient, wherein the single-stranded nucleic acid molecule has, as an expression inhibitory sequence, a sequence inhibiting the expression of a gene causing the disease.

### Claim at position 23

-25. (canceled)
